Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

ConferenceXPHOZAHPositive

AI Analysis

Summary

Ardelyx presented a data analysis evaluating the long-term safety of XPHOZAH (tenapanor) on serum electrolytes and nutrition biomarkers at the National Kidney Foundation's Spring Clinical Meetings in New Orleans.

Outcome Details

Data analysis evaluating long-term impact on serum electrolytes and selected nutrition biomarkers presented at NKF Spring Clinical Meetings

Importance:4/10

Sentiment:

0.40

commercial_stagesafety_datalong_term_analysisconference_presentationkidney_disease

Related Companies

$ARDX

Read the original article

Published by GlobeNewswire Clinical Studies on May 7, 2026 12:01 PM

Read Original